Please login to the form below
Still's disease
This page shows the latest Still's disease news and features for those working in and with pharma, biotech and healthcare.
Alzheimer’s Research UK welcomes ambitions for dementia set out in first women’s health strategy
According to data from the Office of National Statistics, in 2020 the leading cause of death for females in England was dementia and Alzheimer’s disease. ... The strategy also outlines that the government will look for ways to encourage research into
Latest news
-
FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision
the patient-centred outcome of clinical benefit, which has been required of all previous emerging treatments for Alzheimer’s disease,” the institute added. ... Still, patient representatives have counted the approval as a significant win for millions
-
Novartis’ canakinumab failed to improve survival in COVID-19 study
Canakinumab, which Novartis already sells under the brand name Ilaris, is a once-monthly biologic used to treat systemic juvenile idiopathic arthritis and active Still’s disease. ... year. “There’s still an urgent need for effective ways to combat
-
Maintenance OK boosts AstraZeneca’s Lynparza in Europe
to-treat disease.”. ... AZ and Merck’s drug is still in front in terms of sales, bringing in $218m last year, compared to $109m for Zejula and $55m for Rubraca.
-
Pfizer’s leukaemia drug Mylotarg backed for use in EU
The CHMP’s positive opinion could see the drug return to market after almost eight years. ... Kineret (anakinra) in rare inflammatory condition Still’s disease; and Pfizer’s Bosulif (bosutinib) as a treatment for newly-diagnosed Philadelphia
-
Another Alzheimer's bust as Merck & Co stops verubecestat study
Merck Research Laboratories president Roger Perlmutter said the company is "disappointed with this outcome, especially given the lack of treatment options for patients suffering from Alzheimer's disease.".
More from news
Approximately 0 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
A roadmap to the successful treatment of Alzheimer’s disease
Yet more than 100 years after the discovery of Alzheimer’s disease, we still do not have a cure. ... Today, Alzheimer’s disease is typically diagnosed once symptoms are already clinically present.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Pharmacogenomics supports and new era of precision medicine
the molecular basis of a patient’s disease. ... While there is still quite a distance to go, pharmacogenomics is an area full of promise, offering hope for more effective disease management, smoother treatment journeys, and improved patient outcomes.
-
Extraordinary lives: advancing change in rare diseases (Part 2)
This means that, collectively, the number of people living with a rare disease is equivalent to the population of the world's third-largest country (USA). ... While we have come a long way since the inception of Rare Disease Day, there's still plenty of
-
Extraordinary lives: advancing change in rare diseases (Part 2)
This means that, collectively, the number of people living with a rare disease is equivalent to the population of the world’s third-largest country (USA). ... While we have come a long way since the inception of Rare Disease Day, there’s still plenty
-
COUCH Health supports MS Trust raise awareness with a new campaign that puts everyday life into perspective
There’s a wide range of disease modifying therapies, but currently, there’s still no cure. ... To learn more about COUCH Health’s 1mLives initiative, visit: www.1m-lives.com.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Wiley
Wiley is a global leader in research and education. We clear the path for seekers of knowledge, leading the way...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
